The aim of this study is to show that PRPC performed in a single session using a Pascal laser leads to better management of the disease (better rate of regression of neovessels, lower risk of a loss of visual acuity in the long term related to macular edema), a saving of time and better comfort for both patient and doctor.

Inclusion Criteria:

• Diabetes type 1 or 2
• Subjects with severe non-proliferative or early proliferative diabetic retinopathy (according to the Alfediam classification)
• Subjects with central macular thickness less than or equal to 350 µm according to spetralis OCT
• Subjects registered with a social security agency
• Subjects who have provided written informed consent
• Subjects aged 18 or above

Exclusion Criteria:

• Pregnancy
• Breastfeeding women
• Patients presenting a contra-indication to Mydriaticum and Neosynephrine
• History of glaucoma or non-controlled ocular hypertension
• Blindness in one eye
• History of renal insufficiency requiring dialysis, or kidney or pancreas transplantation
• Unbalanced diabetes requiring, in the previous 4 months, intensive insulin therapy.
• Central macular thickness greater than 350 µm
• Visual acuity less than 20/32 measured using an ETDRS chart
• Proliferative diabetic retinopathy associated with "high risk factors" (extensive prepapillary neovessels and/or preretinal or prepapillary neovessels associated with preretinal of intravitreal hemorrhage)
• Macular edema due to causes other than diabetic retinopathy (venous occlusion, uveitis) or occurring in a context of vitreomacular traction
• Already started PRPC
• History of eye surgery or YAG laser capsulotomy performed during the preceding 6 months
• Subjects under legal supervision or guardianship